Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Revolade (Eltrombopag)
Revolade (Eltrombopag) is a vital treatment option for conditions characterized by low platelet counts, such as chronic immune (idiopathic) thrombocytopenic purpura (ITP) and chronic hepatitis C virus (HCV) infection. Additionally, it is prescribed for severe aplastic anemia, underscoring its versatile role in hematologic disorders.
Uses of Revolade (Eltrombopag)
Revolade (Eltrombopag) is utilized:
To manage low platelet counts associated with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
As a therapeutic option for patients with chronic hepatitis C virus (HCV) infection experiencing low platelet levels.
In the treatment regimen for severe aplastic anemia to bolster platelet production.
Benefits of Revolade (Eltrombopag)
Effectively increases platelet counts, thereby mitigating bleeding risks and improving overall hemostasis.
Provides a targeted approach to managing thrombocytopenia in diverse clinical scenarios.
Enhances quality of life by reducing dependency on platelet transfusions and associated complications.
Mechanism of Action of Revolade (Eltrombopag)
Revolade (Eltrombopag) operates by stimulating the production of platelets through interaction with the thrombopoietin receptor (TPO-R), thereby enhancing megakaryocyte proliferation and differentiation. This mechanism supports sustained platelet generation, addressing the underlying causes of thrombocytopenia.